Bristol Myers Squibb vs. Johnson & Johnson: A 2026 Healthcare Sector Showdown

Two Healthcare Giants, Two Very Different Stories

As investors assess the healthcare sector heading deeper into 2026, two names consistently dominate the conversation: Bristol Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ). Despite operating within the same broad industry, these companies present markedly different financial profiles, risk factors, and growth trajectories — making a side-by-side comparison particularly useful for those tracking the pharmaceutical and medical device space.

Bristol Myers Squibb: Deep Value With a Recovery Story

Bristol Myers Squibb has carved out a dominant position in pharmaceutical development, concentrating its efforts on oncology, hematology, and immunology. Its flagship products — Opdivo and Eliquis — anchor a commercial portfolio distributed primarily through wholesalers and specialty pharmacies. The company also maintains key commercial alliances with Merck (NYSE: MRK) and BioNTech (NASDAQ: BNTX) to strengthen its presence in specialized therapeutic areas.

For fiscal year 2025, Bristol Myers posted revenue of nearly $48.2 billion, essentially flat compared to the prior year — down approximately 0.2%. Net income came in at roughly $7.1 billion, translating to a net margin of around 14.6%. That profitability figure represents a meaningful rebound from the previous fiscal year, when the company recorded a substantial net loss tied to specific business restructuring.

On the balance sheet side, Bristol Myers carries a debt-to-equity ratio of approximately 2.6 as of December 2025, indicating a heavier reliance on borrowed capital than many industry peers. The current ratio sits at roughly 1.3, suggesting adequate short-term liquidity, while free cash flow reached nearly $12.8 billion — a figure that underscores the company's ability to generate cash despite elevated debt levels.

Key Risks for BMY

The Inflation Reduction Act poses a notable headwind, enabling government-negotiated pricing on key drugs like Eliquis. Additionally, the loss of market exclusivity for Revlimid has opened the door to generic competition. Pipeline execution remains critical — any delays in clinical trials or regulatory setbacks could weigh on future earnings expectations.

Johnson & Johnson: Scale and Diversification at a Premium

Johnson & Johnson operates across two major business segments: Innovative Medicine and MedTech. The MedTech arm supplies hospitals and surgical centers with orthopedic and vision products, while the pharmaceutical side concentrates on immunology and oncology. This diversified model gives J&J broad exposure across the healthcare ecosystem.

Fiscal 2025 results were notably strong, with revenue reaching approximately $94.2 billion — up nearly 6% year over year. Net income climbed to roughly $26.8 billion, producing an impressive net margin of approximately 28.5%. The company's December 2025 balance sheet reflects a conservative debt-to-equity ratio of just 0.6, considerably lower than Bristol Myers and much of the industry. Free cash flow generation was also substantial at nearly $19.7 billion, with a current ratio of roughly 1.0.

Key Risks for JNJ

Despite its financial strength, Johnson & Johnson continues to navigate significant legal exposure related to its talc-containing products. As of mid-2026, approximately 60,000 cases remain unresolved in the United States, and the litigation recently expanded in the United Kingdom, where it is on track to become the largest product liability case in that country's history. Biosimilar competition — particularly from companies like Amgen (NASDAQ: AMGN) targeting Stelara — adds another layer of near-term pressure. The planned separation of its orthopedics business also introduces execution risk and potential near-term volatility.

Valuation: A Stark Contrast

Perhaps the most striking difference between these two companies is how the market prices them. Based on current estimates, Bristol Myers trades at a forward price-to-earnings ratio of just 9.1, compared to Johnson & Johnson's 22.0. The broader healthcare sector benchmark, represented by the SPDR XLV ETF, sits at approximately 24.8x forward earnings.

The price-to-sales disparity is equally pronounced: Bristol Myers trades at a P/S ratio of 2.4 versus J&J's 6.5. These figures suggest that Bristol Myers is priced at a significant discount relative to both its larger rival and the broader sector.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may vary across data providers.

What Investors Are Watching

For Bristol Myers, the trajectory of its so-called "Growth Portfolio" will be closely monitored as older drugs like Revlimid lose exclusivity protection. Pipeline updates — several of which showed promising early data in the fiscal Q4 2025 report — could serve as meaningful catalysts in the months ahead.

For Johnson & Johnson, resolution of the talc litigation remains a pivotal open question. With tens of thousands of cases still pending and new legal actions emerging internationally, the timeline and ultimate financial impact remain difficult to quantify. Analysts will also be watching closely for updates on the planned orthopedics business separation and its effect on segment performance.

Both companies represent significant forces in global healthcare, each carrying distinct financial characteristics and risk profiles that investors will need to weigh carefully against their own frameworks and objectives.